As a highly efficient biotech company, TenNor Therapeutics is working closely with world leading Contract Research Organizations, academic institutions and hospitals to advance its drug development portfolio.
Taking advantage of its fully integrated drug R&D platform, TenNor has formed a strategic partnership with WuXi AppTec in many areas along the drug R&D value chain, including process optimization, drug substance and drug product manufacturing, drug metabolism and pharmacokinetics, pharmacology, toxicology, regulatory affairs and clinical development.
TenNor is collaborating with Peking University First Hospital, Shanghai Jiaotong University Renji Hospital, Nanchang University First Hospital, Shanghai InnoStar Biotech, Colorado State University and University of Northern Texas Health Science Center to perform mechanism of action, activity against clinical isolates, efficacy in animal models, analytical chemistry, safety pharmacology and toxicology studies.